Study On The Mechanism Of Bioactive Peptide Vglycin For Treatments Of Type 2 Diabetes And Non-alcoholic Fatty Liver Disease

Type 2 diabetesand non-alcoholic fatty liver disease are the world’s widespread metabolic syndromes,obesity is the most important factor of these two diseases,while insulin resistance is one of the common pathogenic mechanisms.From the perspective of metabolomics,the main cause of obesityis excess energy in take and sedentary life style.Obesity can directly lead to insulin resistancein multiple organs and tissues,and promote multiple inflammatory factors which can further aggravates insulin resistance.The typical clinical symptoms of type 2 diabetes are persistent hyperglycemia and insulin resistance,which can result in impaired glucose tolerance.Besides insulin resistance,the pathologic features of non-alcoholic fatty liver disease also include abnormal liver function,hepatic steatosis and increased triglyceride of liver cells.It is important to control the blood glucose and prevent or delay the occurrence of diabetes complications for type 2 diabetes patients.Medical and biological scientists have been working on finding safer and more effective drugs to treat these two diseases.Bioactive peptide Vglycin is a polypeptide of 37 amino acids isolated from germinated pea seeds and soybean seeds.Previous studies have found that Vglycin can normalizes fasting glucose and restores impaired pancreatic function in type 2 diabetic Wistar rats.Based on the pharmaceutical effect and the preliminary experimental results of Vglycin,we believe that Vglycin will have a potential effect on the treatment of type 2 diabetes and even non-alcoholic fatty liver disease.In the present study,we focus on the detecting of Vglycin in regulating the glucose homeostasis,improving insulin sensitivity,and preserving pancreatic islets of type 2 diabetes mice,and the mechanism of Vglycin in body weight losing,improving liver function,decreasing liver triglyceride content and inhibiting hepatocellular lipid synthesis in non-alcoholic fatty liver disease.The results of Vglycin treatment for type 2 diabetesare as follow:(1)Vglycin can reduce the body weight of T2 D mice induced by high-fat diet effectively;(2)Vglycin can restore impaired plasma glucose of T2 D mice level,improve insulin resistance and insulin sensitivity;(3)Vglycin can promote insulin secretion and suppress glucagon secretion under the stimulus ofglucose;(4)Vglycin decreases serum IL-1β in serum,while increases IL-1β and IL-6 in the pancreas,Vglycin ameliorate the Inflammatory environment of pancreas by regulating the expression of proinflammatory factor in serum and pancreas tissue;(5)Vglycin promotes islet β cells,especially mature islet β cells proliferation and inhibits apoptosis of islet β cells,Vglycin could increase the viability of islet β cells.The results of Vglycin treatment for non-alcoholic fatty liver diseaseare as follow:(1)Vglycin inhibits body weight gain and reduces the Lee’s indexin NAFLD mice;(2)Vglycin restores impaired fasting glucose levels and liver enzyme levels,while reduces the serum TG level of NAFLD mice.These results indicate that long term therapy on NAFLD mice by Vglycin could aemlioerate the blood glucose and blood lipid.And the Vglycin is beneficial for relieving the hepatic function;(3)Vglycin inhibits hepatic steatosis,reduces the number and size of lipid droplets in NAFLD mice;(4)Vglycin maintains the cell energy homeostasis through the activation of AMPKβ1 and inhibits lipid synthesisin hepatocyte.Vglycin,an oral bioactive polypeptide derived from a source of legume,has been shown to have medicinal potential to treat type 2 diabetes and non-alcoholic fatty liver disease.However,the refined molecular mechanism and the cellular target of Vglycin need to be further researched.We hope that in the near future,bioactive peptide Vglycin can be developed into a new drug for treating type 2 diabetes and non-alcoholic fatty liver disease for the benefit of patients.